TUXARIN ER
Peakcodeine phosphate and chlorpheniramine maleate
NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2015
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TUXARIN ER is an extended-release oral tablet combining codeine phosphate (an opioid antitussive) and chlorpheniramine maleate (a first-generation antihistamine) for symptomatic cough and upper respiratory allergy relief. The codeine suppresses cough via CNS depression while chlorpheniramine blocks H1 receptors to reduce allergic symptoms. This combination formulation targets patients with cough accompanied by allergic or histamine-mediated symptoms.
Peak5.7 years to LOE
Product is at peak lifecycle stage with no competitive pressure, suggesting stable team investment and focus on retention rather than aggressive expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TUXARIN ER is a stable, peak-stage small-molecule product with minimal competitive pressure, making it a low-risk career assignment focused on market maintenance and customer relationship management. However, the absence of linked job openings and lack of clinical expansion suggest limited growth trajectory; professionals should view this role as a foundation for broader commercial or medical affairs competencies rather than as a high-visibility launch or innovation opportunity.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.